FGFR3 and urinary bladder cancer: To address the dose‐limiting toxicity caused by A2's insufficient targeting capability, LZU‐WZLYCS01, a novel FGFR3‐targeting ADC for bladder cancer with A2 as its cytotoxic payload is developed.